Aerobic Vaginitis (AV), a clinical entity established in early 2000, is still considered an underdiagnosed and underestimated condition. It is an infection characterized by the disturbance in the normal vaginal flora and by significant development of aerobic bacteria during vaginal swab culture.

IASO Group’s Research Team at the Infections Research Center, headed by Mr. Mathaios Falaggas, Professor of Internal medicine-Infectious diseases, and Mr. Nikolaos Legakis, Professor of Microbiology, in collaboration with the physician-scientists Ms Giannoula Tansarli and Mr. Tilemachos Skalidis, published their study in the authoritative scientific journal “European Journal of Clinical Microbiology and Infectious Diseases” regarding the prevalence of inflammatory disorders in the vaginal flora, accompanied by significant development of aerobic bacteria in women with vaginitis symptoms.

Vaginal swabs from 761 women with vaginitis symptoms were prospectively obtained. Of them, 579 were diagnosed with the most common types of vaginitis: fungal vaginitis (mainly from Candida albicans), non-specific bacterial vaginitis (bacterial vaginosis) or trichomonas-induced vaginitis. The rest 23.9% (182 women, 66 of whom were pregnant) presented inflammatory disorder of the vaginal flora, according to specific lab criteria, with significantly high counts of aerobic bacteria in their vaginal swab cultures. Escherichia coli was the bacterium most commonly isolated (45.7% in non pregnant women and 34.8% in pregnant women). Other common bacteria included Group B streptococcus and Enterococcus faecalis.

Considering that the specific group of women, apart from physical, also demonstrated microscopy findings of inflammation, and the fact that other types of vaginitis and diseases were ruled out, it is deducted that the majority of the patients were suffering from aerobic vaginitis. Based on the above research findings during the investigation of cases with suspected vaginitis, the likelihood of a severe vaginal flora disorder causing aerobic vaginits should be examined.

For more press information:
Department of Commercial Management at IASO Group: Ms Nancy Christopoulou, tel: +30 210 6502853, E-mail: [email protected]